Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      New three-year real-world data on Leqembi® presented at CTAD 2026


      News provided by

      BioArctic

      18 Nov, 2026, 16:42 GMT


      STOCKHOLM, November 18, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) study[1]. The data showed that patients treated with Leqembi had a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia compared with a matched natural history cohort through 36 months of treatment. The new analysis included 560 patients treated with Leqembi across 13 clinical sites in the US.

      The data were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston and represent the largest analysis of the ongoing LEADER study reported to date. The results provide further insights into treatment with Leqembi in clinical practice, including disease progression, amyloid clearance, treatment persistence, expanded subcutaneous maintenance treatment experience and safety. The findings were presented alongside an international real-world meta-analysis of approximately 5,000 patients treated with Leqembi.

      LEADER study key findings

      LEADER patients showed slower progression compared to ADNI control[2]:

      • In a pre-specified comparison of patients in LEADER (N=504) with an ADNI-weighted external control cohort (N=573), patients treated with Leqembi had a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia through 36 months (HR 0.24; 95% CI, 0.15–0.39).

      More than 8 in 10 patients remained stable or improved[3]:

      • Among 546 patients whose change in disease stage could be assessed after an average of approximately 18 months of treatment, 81.1% were reported as stable or improved compared with baseline. Of these patients, 75.8% remained stable and 5.3% improved.
      • Results were generally consistent across groups defined by sex, race, ethnicity, APOE genotype and concomitant antithrombotic use.
      • At the time of chart extraction, 87.5% of the 560 patients remained on Leqembi treatment, with an average treatment duration of approximately 19 months.

      Most patients estimated to remain in early Alzheimer's disease:

      • Among all 560 patients in the study, 95.0% were estimated to remain in the early stages of Alzheimer's disease through three years of treatment, based on statistical modeling of observed real-world patient data.

      New real-world evidence shows amyloid clearance:

      • Among 43 patients across six sites performing both baseline and follow-up amyloid PET scans, 77% (33) became amyloid-negative at a median follow-up of 18.1 months. (IQR 16.4–18.7 months).

      Expanding experience with Leqembi maintenance therapy:

      • Of the patients who reached 18 months of treatment, 91.7% remained on Leqembi. A total of 218 patients transitioned to intravenous (IV) maintenance treatment once-every-four-weeks., Following approval of once-weekly subcutaneous (SC) maintenance treatment, 64 patients transitioned to that regimen.
      • Among patients receiving monthly IV maintenance treatment, 71.1% remained stable after an average of 26 months from treatment initiation. Among patients receiving weekly SC maintenance treatment, 76.6% remained stable after an average of 25.1 months.
      • All 64 patients receiving SC maintenance treatment remained on therapy at the time of chart extraction.
      • No ARIA[4] events were reported during the subcutaneous maintenance period, and there were no other safety events of significance. Isolated ARIA-H was reported in 0.5% of patients during the IV maintenance period.

      Clinical outcomes consistent between women and men

      • 79.3% of women (N=300) and 83.3% of men (N=246) in the study were reported as stable or improved3.
      • Treatment duration and persistence were similar across sexes, with 86.0% of females and 88.9% of males remaining on therapy at time of chart extraction.
      • ARIA incidence and severity were generally consistent between female and male patients: any ARIA (14.7% females vs. 17.0% males), ARIA-E (7.5% females vs. 5.5% males), ARIA-H (9.8% females vs. 12.6% males), isolated ARIA-H (7.2% females vs. 11.5% males).

      Safety findings consistent with other real-world experience:

      Overall safety findings in LEADER were consistent with the independent ALZ-NET registry and the US prescribing information for Leqembi.

      • ALZ-NET is a North American voluntary health care provider-enrolled patient network that collects longitudinal clinical, imaging, and safety data in patients treated with FDA-approved AD therapies. Over 1,700 patients taking Leqembi were included in ALZ-NET at the time of data extraction.
      • ARIA-E was observed in 6.6% of patients in LEADER compared with 6.3% in ALZ-NET, while ARIA-H was observed in 11.1% and 10.1% of patients, respectively.
      • Observed ARIA rates were generally consistent regardless of APOE ε4 status, concomitant antithrombotic use, race and ethnicity.

      Additional real-world analysis of approximately 5,000 patients[5]:

      A separate post hoc exploratory analysis presented at CTAD evaluated 16 published real-world Leqembi cohorts across six countries, representing approximately 5,000 patients treated in routine clinical practice.

      • Across the 16 studies, the pooled total ARIA rate was 12.4%, compared with 21.5% in the Phase 3 Clarity AD study. ARIA-E occurred in 4.0% compared with 12.6% in Clarity AD, while ARIA-H occurred in 9.4% compared with 17.3%.
      • Symptomatic ARIA was reported in 0.8% compared with 2.8% in Clarity AD.
      • Treatment discontinuation due to adverse events was 3.2%.

      Limitations of Real-World Studies

      Retrospective real-world studies can be valuable in providing additional information to complement clinical trial data; however, there are potential limitations to consider, including: potential for biases, data completeness and consistency, lack of a control group, interpretation of data due to lack of placebo-controlled arms, and confounding variables, and data inconsistency. Data inconsistency may be mitigated by providing site access to standardized electronic case-report forms.

      The information was released for public disclosure, through the agency of the contact person below, on November 18, 2026, at 5.15 pm CET.

      For further information, please contact: 
      Oskar Bosson, Chief Investor Relations & Communications Officer
      E-mail: oskar.bosson@bioarctic.com
      Telephone: +46 704 107 180

      Jenny Ljunggren, External Communications and Investor Relations Manager
      E-mail: jenny.ljunggren@bioarctic.com
      Telephone: +46 76 013 86 08

      About Leqembi® (lecanemab)

      Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

      Leqembi is approved in 53 countries and is under regulatory review in six countries and regions. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in nine countries and regions, including the US, Japan, China and the United Kingdom, and applications have been filed in eleven countries and regions. In the US, Leqembi Iqlik® is approved for subcutaneous dosing with an autoinjector as a starting dose and maintenance treatment of early Alzheimer's disease. Subcutaneous initiation treatment was approved in China and Japan in September 2026, and applications are under review in four countries.

      Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease has been ongoing since July 2020. These individuals are clinically normal and have intermediate or elevated levels of amyloid in their brains. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

      About the collaboration between BioArctic and Eisai

      BioArctic has a long-term collaboration with Eisai since 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed in 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed in 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

      About BioArctic AB

      BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

      [1] The three-year LEADER Study is a multicenter, retrospective real-world study designed to examine LEQEMBI utilization, treatment persistence, transition to maintenance therapy, safety, cognitive and functional assessments, and healthcare professional (HCP) implementation learnings in diverse U.S. clinical settings for patients with early AD. The study integrated deidentified chart and electronic medical record (EMR) data from 13 U.S. sites, HCP surveys and HCP interviews. This updated analysis included 560 patients with early AD who, as of September 2026, received at least seven LEQEMBI initiation infusions. The maintenance therapy analysis included patients who received biweekly IV initiation treatment for 18 months, followed by at least three months of IV or SC maintenance therapy.

      [2] ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.

      [3] Change in clinical disease stage was defined as:

      • Stable: Patient remaining in the same clinical disease stage (MCI due to AD or mild AD dementia) from baseline throughout the course of LEQEMBI treatment.
      • Improvement: Patient transitioning from mild AD dementia at baseline to MCI due to AD over the course of LEQEMBI treatment.
      • Progression: Patient advancing from MCI at baseline to mild/moderate AD dementia or from mild AD dementia at baseline to moderate AD dementia throughout the course of LEQEMBI treatment.

      [4] ARIA refers to amyloid-related imaging abnormalities that can be observed with anti-amyloid beta antibody treatment and includes ARIA-E, which involves edema/effusion, and ARIA-H, which involves hemosiderin deposition, including cerebral microhemorrhage, cerebral macrohemorrhage and superficial siderosis, as observed on brain magnetic resonance imaging (MRI).

      [5] The meta-analysis on ARIA rates and safety profiles in clinical practice included centers located in the U.S., China, South Korea, Japan, Italy and Israel. Patients were treated between 2023 and 2026 and received at least six months of LEQEMBI treatment.

      This information was brought to you by Cision http://news.cision.com

      https://news.cision.com/bioarctic/r/new-three-year-real-world-data-on-leqembi--presented-at-ctad-2026,c4426529

      The following files are available for download:

      https://mb.cision.com/Main/9978/4426529/4380035.pdf

      New three-year real-world data on Leqembi® presented at CTAD 2026

      Modal title

      Also from this source

      Invitation to presentation of BioArctic's third quarter report for July - September 2026 on November 25 at 9:30 a.m. CET

      BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2026 on Wednesday, November 25,...

      Five-year data of continuous Leqembi® treatment show increasing benefit over time

      BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.